Harnessing and modulating inflammation in strategies for bone regeneration

Tissue Engineering - Part B: Reviews

Volumn 17, Issue 6, 2011, Pages 393-402

  Mountziaris, Paschalia M ^a   Spicer, Patrick P ^a   Kasper, F Kurtis ^a   Mikos, Antonios G ^a  

^a Rice University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-INFLAMMATORY AGENTS; BIOMEDICAL DEVICES; BONE HEALING; BONE REGENERATION; BONE TISSUE; FUTURE DIRECTIONS; IN-VITRO; INFLAMMATORY DISEASE; INFLAMMATORY PROCESS; INFLAMMATORY RESPONSE; INHIBITORY EFFECT;

PATHOLOGY; TISSUE;

BONE;

ANTIINFLAMMATORY AGENT; CELECOXIB; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; GAMMA INTERFERON; IBUPROFEN; INTERLEUKIN 1; INTERLEUKIN 4; INTERLEUKIN 6; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2 RECEPTOR STIMULATING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; RUSALATIDE; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BONE INJURY; BONE REGENERATION; CHRONIC INFLAMMATION; DEVICE; DRUG TARGETING; FRACTURE; FRACTURE HEALING; HUMAN; IMPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTI-INFLAMMATORY AGENTS; BONE AND BONES; BONE REGENERATION; HUMANS; INFLAMMATION; WOUND HEALING;

EID: 81755166884     PISSN: 19373368     EISSN: 19373376     Source Type: Journal    
DOI: 10.1089/ten.teb.2011.0182     Document Type: Review

References (107)

1. Mountziaris, P.M., and Mikos, A.G. Modulation of the inflammatory response for enhanced bone tissue regeneration. Tissue Eng Part B Rev 14, 179, 2008.
2. Kolar, P., Schmidt-Bleek, K., Schell, H., Gaber, T., Toben, D., Schmidmaier, G., Perka, C., Buttgereit, F., and Duda, G.N. The early fracture hematoma and its potential role in fracture healing. Tissue Eng Part B Rev 16, 427, 2010.
3. Takayanagi, H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 5, 667, 2009.
4. Schett, G., and David, J.-P. The multiple faces of autoimmune-mediated bone loss. Nat Rev Endocrinol 6, 698, 2010.
5. Pape, H.-C., Marcucio, R., Humphrey, C., Colnot, C., Knobe, M., and Harvey, E.J. Trauma-induced inflammation and fracture healing. J Orthop Trauma 24, 522, 2010.
6. Kon, T., Cho, T.-J., Aizawa, T., Yamazaki, M., Nooh, N., Graves, D.T., Gerstenfeld, L.C., and Einhorn, T.A. Expression of osteoprotegerin, receptor activator of NF-kB ligand (osteoprotegrin ligand) and related pro-inflammatory cytokines during fracture healing. J Bone Miner Res 16, 1004, 2001.
7. Cho, T.-J., Gerstenfeld, L.C., and Einhorn, T.A. Differential temporal expression of members of the transforming growth factor b superfamily during murine fracture healing. J Bone Miner Res 17, 513, 2002.
8. Rundle, C.H., Wang, H., Yu, H., Chadwick, R.B., Davis, E.I., Wegedal, J.E., Lau, K.-H.W., Mohan, S., Ryaby, J.T., and Baylink, D.J. Microarray analysis of gene expression during the inflammation and endochondral bone formation stages of rat femur fracture repair. Bone 38, 521, 2006.
9. Kitaori, T., Ito, H., Schwarz, E.M., Tsutsumi, R., Yoshitomi, H., Oishi, S., Nakano, M., Fujii, N., Nagasawa, T., and Nakamura, T. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum 60, 813, 2009.
10. Thevenot, P.T., Nair, A.M., Shen, J., Lotfi, P., Ko, C.-Y., and Tang, L. The effect of incorporation of SDF-1[alpha] into PLGA scaffolds on stem cell recruitment and the inflammatory response. Biomaterials 31, 3997, 2010.
11. Bocker, W., Docheva, D., Prall, W., Egea, V., Pappou, E., Rossmann, O., Popov, C., Mutschler, W., Ries, C., and Schieker, M. IKK-2 is required for TNF-a-induced invasion and proliferation of human mesenchymal stem cells. J Mol Med 86, 1183, 2008.
12. Glass, G.E., Chan, J.K., Freidin, A., Feldmann, M., Horwood, N.J., and Nanchahal, J. TNF-a promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells. Proc Natl Acad Sci USA 108, 1585, 2011.
13. Sfeir, C., Ho, L., Doll, B.A., Azari, K., and Hollinger, J.O. Fracture repair. In: Lieberman, J.R., and Friedlaender, G.E., eds. Bone Regeneration and Repair. Totowa: Humana Press, 2005, pp. 21-44.
14. Gerstenfeld, L.C., Cho, T.-J., Kon, T., Aizawa, T., Tsay, A., Fitch, J., Barnes, G.L., Graves, D.T., and Einhorn, T.A. Impaired fracture healing in the absence of TNF-a signaling: the role of TNF-a in endochondral cartilage resorption. J Bone Miner Res 18, 1584, 2003.
15. Yang, X., Ricciardi, B.F., Hernandez-Soria, A., Shi, Y., Camacho, N.P., and Bostrom, M. Callus mineralization and maturation are delayed during fracture healing in interleukin-6 knockout mice. Bone 41, 928, 2007.
16. Schmidt-Bleek, K., Schell, H., Kolar, P., Pfaff, M., Perka, C., Buttgereit, F., Duda, G., and Lienau, J. Cellular composition of the initial fracture hematoma compared to a muscle hematoma: a study in sheep. J Orthop Res 27, 1147, 2009.
17. Martin, P., D'Souza, D., Martin, J., Grose, R., Cooper, L., Maki, R., and McKercher, S.R. Wound healing in the PU.1 null mouse-tissue repair is not dependent on inflammatory cells. Curr Biol 13, 1122, 2003.
18. Toben, D., Schroeder, I., El Khassawna, T., Mehta, M., Hoffmann, J.E., Frisch, J., Schell, H., Lienau, J., Serra, A., Radbruch, A., and Duda, G.N. Fracture healing is accelerated in the absence of the adaptive immune system. J Bone Miner Res 26, 113, 2011.
19. Colburn, N.T., Zaal, K.J.M., Wang, F., and Tuan, R.S. A role for g/d T cells in a mouse model of fracture healing. Arthritis Rheum 60, 1694, 2009.
20. Xing, Z., Lu, C., Hu, D., Miclau, T., and Marcucio, R.S. Rejuvenation of the inflammatory system stimulates fracture repair in aged mice. J Orthop Res 28, 1000, 2010.
21. Hofmann, A., Ritz, U., Hessmann, M.H., Schmid, C., Tresch, A., Rompe, J.D., Meurer, A., and Rommens, P.M. Cell viability, osteoblast differentiation, and gene expression are altered in human osteoblasts from hypertrophic fracture non-unions. Bone 42, 894, 2008.
22. Lienau, J., Schmidt-Bleek, K., Peters, A., Weber, H., Bail, H.J., Duda, G.N., Perka, C., and Schell, H. Insight into the molecular pathophysiology of delayed bone healing in a sheep model. Tissue Eng Part A 16, 191, 2010.
23. Pettit, A.R., Ji, H., von Stechow, D., Muller, R., Goldring, S.R., Choi, Y., Benoist, C., and Gravallese, E.M. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159, 1689, 2001.
24. Guo, R., Yamashita, M., Zhang, Q., Zhou, Q., Chen, D., Reynolds, D.G., Awad, H.A., Yanoso, L., Zhao, L., Schwarz, E.M., Zhang, Y.E., Boyce, B.F., and Xing, L. Ubiquitin ligase smurf1 mediates tumor necrosis factorinduced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins. J Biol Chem 283, 23084, 2008.
25. Alblowi, J., Kayal, R.A., Siqueria, M., McKenzie, E., Krothapalli, N., McLean, J., Conn, J., Nikolajczyk, B., Einhorn, T.A., Gerstenfeld, L., and Graves, D.T. High levels of tumor necrosis factor-{alpha} contribute to accelerated loss of cartilage in diabetic fracture healing. Am J Pathol 175, 1574, 2009.
26. Pape, H.-C., Schmidt, R.E., Rice, J., van Griensven, M., das Gupta, R., Krettek, C., and Tscherne, H. Biochemical changes after trauma and skeletal surgery of the lower extremity: quantification of the operative burden. Crit Care Med 28, 3441, 2000.
27. Miller, R.R., Cappola, A.R., Shardell, M.D., Hawkes, W.G., Yu-Yahiro, J.A., Hebel, J.R., and Magaziner, J. Persistent changes in interleukin-6 and lower extremity function following hip fracture. J Gerontol A Biol Sci Med Sci 61, 1053, 2006.
28. Caparbo, V., Prada, F., Silva, C., Regio, P., and Pereira, R. Serum from children with polyarticular juvenile idiopathic arthritis (PJIA) inhibits differentiation, mineralization and may increase apoptosis of human osteoblasts in vitro. Clin Rheumatol 28, 71, 2009.
29. Aspenberg, P. Drugs and fracture repair. Acta Orthop 76, 741, 2005.
30. Xian, C.J., and Zhou, X.-F. Treating skeletal pain: limitations of conventional anti-inflammatory drugs, and antineurotrophic factor as a possible alternative. Nat Clin Pract Rheum 5, 92, 2009.
31. Jaiswal, N., Haynesworth, S.E., Caplan, A.I., and Bruder, S.P. Osteogenic differentiation of purified, cultureexpanded human mesenchymal stem cells in vitro. J Cell Biochem 64, 295, 1997.
32. van der Goes, M.C., Jacobs, J.W.G., Boers, M., Andrews, T., Blom-Bakkers, M.A.M., Buttgereit, F., Caeyers, N., Cutolo, M., Da Silva, J.A.P., Guillevin, L., Kirwan, J.R., Rovensky, J., Severijns, G., Webber, S., Westhovens, R., and Bijlsma, J.W.J. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 69, 1913, 2010.
33. Hoes, J.N., Jacobs, J.W.G., Buttgereit, F., and Bijlsma, J.W.J. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 6, 693, 2010.
34. Ho, M.L., Chang, J.K., and Wang, G.J. Anti-inflammatory drug effects on bone repair and remodeling in rabbits. Clin Orthop Relat Res 313, 270, 1995.
35. Lyritis, G., Papadopoulou, Z., Nikiforidis, P., Batrinos, M., and Varonos, D. Effects of cortisone and anabolic steroid upon plasma hydroxyproline during fracture healing in rabbits. Acta Orthop Scand 46, 25, 1975.
36. Waters, R.V., Gamradt, S.C., Asnis, P., Vickery, B.H., Avnur, Z., Hill, E., and Bostrom, M. Systemic corticosteroids inhibit bone healing in a rabbit ulnar osteotomy model. Acta Orthop Scand 71, 316, 2000.
37. de Castro, L.F., Lozano, D., Dapia, S., Portal-Nunez, S., Caeiro, J.R., Gomez-Barrena, E., and Esbrit, P. Role of the N-and C-terminal fragments of parathyroid-hormonerelated protein as putative therapies to improve bone regeneration under high glucocorticoid treatment. Tissue Eng Part A 16, 1157, 2010.
38. Gilley, R., Wallace, L., Bourgeault, C., Kidder, L., and Bechtold, J. OP-1 augments glucocorticoid-inhibited fracture healing in a rat fracture model. Clin Orthop Relat Res 467, 3104, 2009.
39. Weber, A.J., Li, G., Kalak, R., Street, J., Buttgereit, F., Dunstan, C.R., Seibel, M.J., and Zhou, H. Osteoblasttargeted disruption of glucocorticoid signalling does not delay intramembranous bone healing. Steroids 75, 282, 2010.
40. Kaplan, F.S., Le Merrer, M., Glaser, D.L., Pignolo, R.J., Goldsby, R.E., Kitterman, J.A., Groppe, J., and Shore, E.M. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol 22, 191, 2008.
41. Wang, Q., Wang, J., Lu, Q., Detamore, M.S., and Berkland, C. Injectable PLGA based colloidal gels for zero-order dexamethasone release in cranial defects. Biomaterials 31, 4980, 2010.
42. Shi, X., Ren, L., Tian, M., Yu, J., Huang, W., Du, C., Wang, D.-A., and Wang, Y. In vivo and in vitro osteogenesis of stem cells induced by controlled release of drugs from microspherical scaffolds. J Mater Chem 20, 9140, 2010.
43. Castano-Izquierdo, H., Alvarez-Barreto, J., van den Dolder, J., Jansen, J.A., Mikos, A.G., and Sikavitsas, V.I. Pre-culture period of mesenchymal stem cells in osteogenic media influences their in vivo bone forming potential. J Biomed Mater Res A 82, 129, 2007.
44. Oliveira, J.M., Kotobuki, N., Tadokoro, M., Hirose, M., Mano, J.F., Reis, R.L., and Ohgushi, H. Ex vivo culturing of stromal cells with dexamethasone-loaded carboxymethylchitosan/poly(amidoamine) dendrimer nanoparticles promotes ectopic bone formation. Bone 46, 1424, 2010.
45. Haisch, A., Wanjura, F., Radke, C., Leder-Johrens, K., Groger, A., Endres, M., Klaering, S., Loch, A., and Sittinger, M. Immunomodulation of tissue-engineered transplants: in vivo bone generation from methylprednisolone- stimulated chondrocytes. Eur Arch Otorhinolaryngol 261, 216, 2004.
46. Miller, M., Ivkovic, A., Porter, R., Harris, M., Estok, D., Smith, R., Evans, C., and Vrahas, M. Autologous bone grafting on steroids: preliminary clinical results. A novel treatment for nonunions and segmental bone defects. Int Orthop 35, 599, 2011.
47. Goodman, S.B., Jiranek, W., Petrow, E., and Yasko, A.W. The effects of medications on bone. J Am Acad Orthop Surg 15, 450, 2007.
48. Pieringer, H., Stuby, U., and Biesenbach, G. Patients with rheumatoid arthritis undergoing surgery: how should we deal with anti-rheumatic treatment? Semin Arthritis Rheum 36, 278, 2007.
49. Nam, J.L., Winthrop, K.L., van Vollenhoven, R.F., Pavelka, K., Valesini, G., Hensor, E.M.A., Worthy, G., Landewé, R., Smolen, J.S., and Emery, P. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69, 976, 2010.
50. Den Broeder, A.A., Creemers, M.C.W., Fransen, J., De Jong, E., De Rooij, D.J.R., Wymenga, A., De Waal-Malefijt, M., and Van Den Hoogen, F.H.J. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34, 689, 2007.
51. Hirano, Y., Kojima, T., Kanayama, Y., Shioura, T., Hayashi, M., Kida, D., Kaneko, A., Eto, Y., and Ishiguro, N. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol 29, 495, 2010.
52. Kawakami, K., Ikari, K., Kawamura, K., Tsukahara, S., Iwamoto, T., Yano, K., Sakuma, Y., Tokita, A., and Momohara, S. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-[alpha] blockers: perioperative interruption of tumour necrosis factor-[alpha] blockers decreases complications? Rheumatology 49, 341, 2010.
53. Ruyssen-Witrand, A., Gossec, L., Salliot, C., Luc, M., Duclos, M., Guignard, S., and Dougados, M. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 25, 430, 2007.
54. Malviya, A., Kuiper, J.H., Makwana, N., Laing, P., and Ashton, B. The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study. J Orthop Surg Res 4, 17, 2009.
55. Abdul-Hadi, O., Parvizi, J., Austin, M.S., Viscusi, E., and Einhorn, T. Nonsteroidal anti-inflammatory drugs in orthopaedics. J Bone Joint Surg Am 91, 2020, 2009.
56. Cottrell, J., and O'Connor, J.P. Effect of non-steroidal antiinflammatory drugs on bone healing. Pharmaceuticals 3, 1668, 2010.
57. Simon, A.M., Manigrasso, M.B., and O'Connor, J.P. Cyclooxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 17, 963, 2002.
58. Zhang, X., Schwarz, E.M., Young, D.A., Puzas, J.E., Rosier, R.N., and O'Keefe, R.J. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is crtically involved in bone repair. J Clin Invest 109, 1405, 2002.
59. Dimmen, S., Nordsletten, L., and Madsen, J. Parecoxib and indomethacin delay early fracture healing: a study in rats. Clin Orthop 467, 1992, 2009.
60. Gerstenfeld, L.C., Al-Ghawas, M., Alkhiary, Y.M., Cullinane, D.M., Krall, E.A., Fitch, J.L., Webb, E.G., Thiede, M.A., and Einhorn, T.A. Selective and nonselective Cyclooxygenase-2 inhibitors and experimental fracturehealing. J Bone Joint Surg Am 89, 114, 2007.
61. O'Connor, J.P., Capo, J.T., Tan, V., Cottrell, J.A., Manigrasso, M.B., Bontempo, N., and Parsons, J.R. A comparison of the effects of ibuprofen and rofecoxib on rabbit fibula osteotomy healing. Acta Orthop 80, 597, 2009.
62. Akritopoulos, P., Papaioannidou, P., Hatzokos, I., Haritanti, A., Iosifidou, E., Kotoula, M., and Mirtsou-Fidani, V. Parecoxib has non-significant long-term effects on bone healing in rats when administered for a short period after fracture. Arch Orthop Trauma Surg 129, 1427, 2009.
63. Simon, A.M., and O'Connor, J.P. Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture healing. J Bone Joint Surg Am 89, 500, 2007.
64. Xie, C., Ming, X., Wang, Q., Schwarz, E.M., Guldberg, R.E., O'Keefe, R.J., and Zhang, X. COX-2 from the injury milieu is critical for the initiation of periosteal progenitor cell mediated bone healing. Bone 43, 1075, 2008.
65. Giannoudis, P.V., MacDonald, D.A., Matthews, S.J., Smith, R.M., Furlong, A.J., and De Boer, P. Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal antiinflammatory drugs. J Bone Joint Surg Br 82, 655, 2000.
66. Bhattacharyya, T., Levin, R., Vrahas, M.S., and Solomon, D.H. Nonsteroidal anti-inflammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum 53, 364, 2005.
67. Vavken, P., Castellani, L., and Sculco, T. Prophylaxis of heterotopic ossification of the hip: systematic review and meta-analysis. Clin Orthop Relat Res 467, 3283, 2009.
68. Neal, B.C., Rodgers, A., Clark, T., Gray, H., Reid, I.R., Dunn, L., and MacMahon, S.W. A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. Acta Orthop Scand 71, 122, 2000.
69. Burd, T.A., Hughes, M.S., and Anglen, J.O. Heterotopic ossification prohylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br 85, 700, 2003.
70. Yamakawa, K., Kamekura, S., Kawamura, N., Saegusa, M., Kamei, D., Murakami, M., Kudo, I., Uematsu, S., Akira, S., Chung, U.-I., Nakamura, K., and Kawaguchi, H. Association of microsomal prostaglandin E synthase 1 deficiency with impaired fracture healing, but not with bone loss or osteoarthritis, in mouse models of skeletal disorders. Arthritis Rheum 58, 172, 2008.
71. Yamaguchi, T., Takada, Y., Maruyama, K., Shimoda, K., Arai, Y., Nango, N., Kosaki, N., Takaishi, H., Toyama, Y., and Matsuo, K. Fra-1/AP-1 impairs inflammatory responses and chondrogenesis in fracture healing. J Bone Miner Res 24, 2056, 2009.
72. Zhang, M., Ho, H.-C., Sheu, T.-J., Breyer, M.D., Flick, L.M., Jonason, J.H., Awad, H.A., Schwarz, E.M., and O'Keefe, R.J. EP1-/-mice have enhanced osteoblast differentiation and accelerated fracture repair. J Bone Miner Res 26, 792, 2011.
73. Xie, C., Liang, B., Xue, M., Lin, A.S.P., Loiselle, A., Schwarz, E.M., Guldberg, R.E., O'Keefe, R.J., and Zhang, X. Rescue of impaired fracture healing in COX-2-/-mice via activation of prostaglandin E2 receptor subtype 4. Am J Pathol 175, 772, 2009.
74. Paralkar, V.M., Borovecki, F., Ke, H., Cameron, K.O., Lefker, B., Grasser, W.A., Owen, T.A., Li, M., DaSilva-Jardine, P., Zhou, M., Dunn, R.L., Dumont, F., Korsmeyer, R., Krasney, P., Brown, T.A., Plowchalk, D., Vukicevic, S., and Thompson, D.D. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci USA 100, 6736, 2003.
75. Tanaka, M., Sakai, A., Uchida, S., Tanaka, S., Nagashima, M., Katayama, T., Yamaguchi, K., and Nakamura, T. Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats. Bone 34, 940, 2004.
76. Kamolratanakul, P., Hayata, T., Ezura, Y., Kawamata, A., Hayashi, C., Yamamoto, Y., Hemmi, H., Nagao, M., Hanyu, R., Notomi, T., Nakamoto, T., Amagasa, T., Akiyoshi, K., and Noda, M. Nanogel-based scaffold delivery of prostaglandin E2 receptor (EP4) specific agonist in combination with low dosage of growth factor heals critical size bone defect. Arthritis Rheum 63, 1021, 2011.
77. Wixted, J.J., Fanning, P., Rothkopf, I., Stein, G., and Lian, J. Arachidonic acid, eicosanoids, and fracture repair. J Orthop Trauma 24, 539, 2010.
78. Manigrasso, M.B., and O'Connor, J.P. Accelerated fracture healing in mice lacking the 5-lipoxygenase gene. Acta Orthop 81, 748, 2010.
79. Cottrell, J.A., and O'Connor, J.P. Pharmacological inhibition of 5-lipoxygenase accelerates and enhances fracturehealing. J Bone Joint Surg Am 91, 2653, 2009.
80. Wixted, J.J., Fanning, P.J., Gaur, T., O'Connell, S.L., Silva, J., Mason-Savas, A., Ayers, D.C., Stein, G.S., and Lian, J.B. Enhanced fracture repair by leukotriene antagonism is characterized by increased chondrocyte proliferation and early bone formation: a novel role of the cysteinyl LT-1 receptor. J Cell Physiol 221, 31, 2009.
81. Gerstenfeld, L.C., Cho, T.J., Kon, T., Aizawa, T., Cruceta, J., Graves, B.D., and Einhorn, T.A. Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling. Cells Tissues Organs 169, 285, 2001.
82. Crisostomo, P.R., Wang, Y., Markel, T.A., Wang, M., Lahm, T., and Meldrum, D.R. Human mesenchymal stem cells stimulated by TNF-{alpha}, LPS, or hypoxia produce growth factors by an NF{kappa}B-but not JNK-dependent mechanism. Am J Physiol Cell Physiol 294, C675, 2008.
83. Mountziaris, P.M., Tzouanas, S.N., and Mikos, A.G. Dose effect of tumor necrosis factor-[alpha] on in vitro osteogenic differentiation of mesenchymal stem cells on biodegradable polymeric microfiber scaffolds. Biomaterials 31, 1666, 2010.
84. Balga, R., Wetterwald, A., Portenier, J., Dolder, S., Mueller, C., and Hofstetter, W. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro. Bone 39, 325, 2006.
85. Iqbal, J., Sun, L., Kumar, T.R., Blair, H.C., and Zaidi, M. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci USA 103, 14925, 2006.
86. Hess, K., Ushmorov, A., Fiedler, J., Brenner, R.E., and Wirth, T. TNF[alpha] promotes osteogenic differentiation of human mesenchymal stem cells by triggering the NF-[kappa]B signaling pathway. Bone 45, 367, 2009.
87. Ding, J., Ghali, O., Lencel, P., Broux, O., Chauveau, C., Devedjian, J.C., Hardouin, P., and Magne, D. TNF-[alpha] and IL-1[beta] inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. Life Sci 84, 499, 2009.
88. Paula-Silva, F.W.G., Ghosh, A., Silva, L.A.B., and Kapila, Y.L. TNF-{alpha} promotes an odontoblastic phenotype in dental pulp cells. J Dent Res 88, 339, 2009.
89. Lacey, D.C., Simmons, P.J., Graves, S.E., and Hamilton, J.A. Proinflammatory cytokines inhibit osteogenic differentiation from stem cells: implications for bone repair during inflammation. Osteoarthritis Cartilage 17, 735, 2009.
90. Lin, C.-C., Metters, A.T., and Anseth, K.S. Functional PEGpeptide hydrogels to modulate local inflammation induced by the pro-inflammatory cytokine TNF[alpha]. Biomaterials 30, 4907, 2009.
91. Lange, J., Sapozhnikova, A., Lu, C., Hu, D., Li, X., Miclau, T., and Marcucio, R.S. Action of IL-1b during fracture healing. J Orthop Res 28, 778, 2010.
92. Lee, Y.-M., Fujikado, N., Manaka, H., Yasuda, H., and Iwakura, Y. IL-1 plays an important role in the bone metabolism under physiological conditions. Int Immunol 22, 805, 2010.
93. Ben David, D., Reznick, A., Srouji, S., and Livne, E. Exposure to pro-inflammatory cytokines upregulates MMP-9 synthesis by mesenchymal stem cells-derived osteoprogenitors. Histochem Cell Biol 129, 589, 2008.
94. Li, Y., Backesjo, C.-M., Haldosen, L.-A., and Lindgren, U. IL-6 receptor expression and IL-6 effects change during osteoblast differentiation. Cytokine 43, 165, 2008.
95. Rozen, N., Lewinson, D., Bick, T., Jacob, Z.C., Stein, H., and Soudry, M. Fracture repair: modulation of fracture-callus and mechanical properties by sequential application of IL-6 following PTH 1-34 or PTH 28-48. Bone 41, 437, 2007.
96. Lewis, D.B., Liggitt, H.D., Effmann, E.L., Motley, S.T., Teitelbaum, S.L., Jepsen, K.J., Goldstein, S.A., Bonadio, J., Carpenter, J., and Perlmutter, R.M. Osteoporosis induced in mice by overproduction of interleukin-4. Proc Natl Acad Sci USA 90, 11618, 1993.
97. Silfversward, C.-J., Sisask, G., Larsson, S., Ohlsson, C., Frost, A., Ljunggren, O., and Nilsson, O. Bone formation in interleukin-4 and interleukin-13 depleted mice. Acta Orthop 79, 410, 2008.
98. Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., Nakamura, K., and Taniguchi, T. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-g. Nature 408, 600, 2000.
99. Tajima, K., Takaishi, H., Takito, J., Tohmonda, T., Yoda, M., Ota, N., Kosaki, N., Matsumoto, M., Ikegami, H., Nakamura, T., Kimura, T., Okada, Y., Horiuchi, K., Chiba, K., and Toyama, Y. Inhibition of STAT1 accelerates bone fracture healing. J Orthop Res 28, 937, 2010.
100. Li, X., Wang, H., Touma, E., Qi, Y., Rousseau, E., Quigg, R.J., and Ryaby, J.T. TP508 accelerates fracture repair by promoting cell growth over cell death. Biochem Biophys Res Commun 364, 187, 2007.
101. Wang, H., Li, X., Tomin, E., Doty, S.B., Lane, J.M., Carney, D.H., and Ryaby, J.T. Thrombin peptide (TP508) promotes fracture repair by up-regulating inflammatory mediators, early growth factors, and increasing angiogenesis. J Orthop Res 23, 671, 2005.
102. Hedberg, E.L., Kroese-Deutman, H.C., Shih, C.K., Crowther, R.S., Carney, D.H., Mikos, A.G., and Jansen, J.A. Effect of varied release kinetics of the osteogenic thrombin peptide TP508 from biodegradable, polymeric scaffolds on bone formation in vivo. J Biomed Mater Res A 72, 343, 2005.
103. Sheller, M.R., Crowther, R.S., Kinney, J.H., Yang, J., Di Jorio, S., Breunig, T., Carney, D.H., and Ryaby, J.T. Repair of rabbit segmental defects with the thrombin peptide, TP508. J Orthop Res 22, 1094, 2004.
104. Carney, D.H., and Olszewska-Pazdrak, B. Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair? Expert Opin Pharmacother 9, 2717, 2008.
105. Asagiri, M., Hirai, T., Kunigami, T., Kamano, S., Gober, H.-J., Okamoto, K., Nishikawa, K., Latz, E., Golenbock, D.T., Aoki, K., Ohya, K., Imai, Y., Morishita, Y., Miyazono, K., Kato, S., Saftig, P., and Takayanagi, H. Cathepsin kdependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 319, 624, 2008.
106. Caplan, A.I. Why are MSCs therapeutic? New data: new insight. J Pathol 217, 318, 2009.
107. Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A.I., Zhao, R.C., and Shi, Y. Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2, 141, 2008.